par Vekemans, Marie-Christiane;Doyen, Chantal;Caers, Jo;Wu, Ka Lung;Kentos, Alain 
;Mineur, Philippe;Michaux, Lucienne;Delforge, Michel;Meuleman, Nathalie
Référence Acta Clinica Belgica (English ed. Printed), 77, 2, page (445-461)
Publication Publié, 2022
;Mineur, Philippe;Michaux, Lucienne;Delforge, Michel;Meuleman, Nathalie Référence Acta Clinica Belgica (English ed. Printed), 77, 2, page (445-461)
Publication Publié, 2022
Article révisé par les pairs
| Résumé : | With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice. |
